Changing refractive outcomes with increasing astigmatism at longer-term follow-up for infant cataract surgery

C Samarawickrama1,2, Y-C Li2, N Kanapathipillai2

  • 1Sydney Eye Hospital, Sydney, New South Wales, Australia.

Eye (London, England)
|July 16, 2016
PubMed

Insights

Infant cataract surgery with intraocular lens (IOL) insertion requires frequent refraction monitoring in the first two years due to rapid refractive changes. Astigmatism management is also crucial for long-term ocular health.

Area of Science:

  • Ophthalmology
  • Pediatric ophthalmology
  • Refractive surgery outcomes

Background:

  • Infant cataract surgery necessitates intraocular lens (IOL) implantation.
  • Long-term refractive and ocular health data following primary IOL insertion in infants are limited.

Purpose of the Study:

  • To evaluate longer-term refractive outcomes after primary intraocular lens (IOL) insertion in infant cataract patients.
  • To assess ocular health complications in this cohort.

Main Methods:

  • Retrospective review of infant cataract cases (surgery before 12 months) between 2003-2006.
  • IOL power calculation using SRK/T formula with age-based hyperopic targets.
  • Statistical analysis using locally weighted scatterplot smoothing and mixed models.

Main Results:

  • Spherical equivalent refraction changed significantly in the first 2 years, then stabilized.
  • Cylinder increased by approximately 0.57 diopters/year until age 5.
  • Lens reproliferation (58%) was the most common complication; all children developed strabismus.

Conclusions:

  • Frequent refractive monitoring is essential in the first two years post-surgery.
  • Management of evolving astigmatism is important for visual development.
  • Early IOL intervention in infant cataracts requires ongoing monitoring for refractive and ocular health.

Related Concept Videos

Focusing of Light in the Eye01:16

Focusing of Light in the Eye

Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
7.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.5K
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.6K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K